Clinical Trial

CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-08-08; most recent amendment 2025-07-31.
Status change: Not Yet Recruiting → Recruiting 2024-02-12
Trial Details
NCT Number NCT05994690
Lead Sponsor Princess Maxima Center for Pediatric Oncology
Collaborators: European Commission
Conditions Acute Myeloid Leukemia in Children
Enrollment 905 participants
Start Date 2023-07-14
Primary Completion 2031-03 (estimated)
Study Completion 2035-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-05